Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near the end of life. We evaluat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Parikh, Ravi B., Galsky, Matthew D., Gyawali, Bishal, Riaz, Fauzia, Kaufmann, Tara L., Cohen, Aaron B., Adamson, Blythe J.S., Gross, Cary P., Meropol, Neal J., Mamtani, Ronac
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Brief Communications
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656487/
https://ncbi.nlm.nih.gov/pubmed/30944183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0039
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky